New insider activity at Oragenics ( (OGEN) ) has taken place on June 18, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Odyssey Health, Inc., a significant shareholder, has recently sold 7,044 shares of Oragenics stock, amounting to a transaction value of $30,407.
Recent Updates on OGEN stock
Oragenics has recently announced a 1-for-30 reverse stock split effective June 3, 2025, to maintain its listing on the NYSE American and to increase the market price per share. This decision aims to align with investor expectations and strengthen the company’s capital markets presence. Despite this move, Oragenics is facing significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues. These challenges contribute to a low financial performance score and unfavorable valuation metrics, resulting in a negative outlook for the stock. Technical indicators also reflect weak stock momentum, further exacerbating the negative sentiment.
Spark’s Take on OGEN Stock
According to Spark, TipRanks’ AI Analyst, OGEN is a Underperform.
Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock’s fundamental and technical weaknesses are significant, resulting in a low overall score.
To see Spark’s full report on OGEN stock, click here.
More about Oragenics
YTD Price Performance: -60.56%
Average Trading Volume: 207,178
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.11M